58 results match your criteria: "and Ruhr-University[Affiliation]"
J Rheumatol
October 2020
U. Kiltz, MD, PhD, Rheumatologist, J. Braun, MD, Professor of Rheumatology, Head of Department, Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Bochum, Germany.
Open Access Rheumatol
August 2020
Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University, Bochum, Germany.
Objective: In 2016, ASAS and EULAR made joint recommendations for the management of patients with spondyloarthritis. Although Global and European perspectives are important, they cannot accurately reflect the situation for all patients in all countries and regions. As such, the group worked to tailor the existing international recommendations to suit the specific demographic needs of local populations in the Gulf region, with a specific focus on Kuwait.
View Article and Find Full Text PDFArthritis Rheumatol
January 2021
Rheumazentrum Ruhrgebiet, Herne, Germany, and Ruhr-University Bochum, Bochum, Germany.
Objective: To report the primary (1-year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA).
Methods: A total of 555 patients were randomized (1:1:1) to receive subcutaneous secukinumab 150 mg with a loading dose (loading dose [LD] group), secukinumab 150 mg without a loading dose (non-loading dose [NL] group), or placebo weekly and then every 4 weeks starting at week 4. The NL group received placebo at weeks 1, 2, and 3 to maintain blinding.
Joint Bone Spine
October 2020
Inserm, Institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 56, boulevard Vincent-Auriol, 75646 Paris, France; Rheumatology department, Pitié-Salpêtrière hospital, AP-HP, 47-83 boulevard de l'Hôpital, 75013 Paris, France.
Objective: Sleep quality is diminished in patients with psoriatic arthritis (PsA) and close to 40% of PsA patients consider sleep difficulties a priority domain. This work analyzes determinants of impaired sleep in patients with PsA.
Methods: This was a cross-sectional analysis of an observational study (ReFlap, NCT NCT03119805), which included adult patients with definite PsA with≥2 years disease duration from 14 countries.
Eur Stroke J
March 2020
Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Arthritis Care Res (Hoboken)
December 2020
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique and Pitié Salpêtrière Hospital, AP-HP, Paris, France.
Objective: Sex differences may modify symptoms, disease expression, and treatment effects. The objective of this study was to evaluate the link between life impact and sex in psoriatic arthritis (PsA).
Methods: Remission and Flare in Psoriatic Arthritis (ReFlaP; ClinicalTrials.
Clin Exp Rheumatol
September 2020
Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche, University of Turin, Italy.
There is growing evidence that the development of rheumatoid arthritis (RA) is a multistep process. The European League Against Rheumatism (EULAR) identified different phases before the onset of RA, from the presence of genetic and environmental risk factors for RA, towards clinically suspected arthralgia and undifferentiated arthritis. Currently, a new definition of "window of opportunity" is emerging; this states that the window could even lie in preclinical phase of RA, preceding diagnosis or fulfillment of classification criteria for RA.
View Article and Find Full Text PDFArthritis Rheumatol
December 2019
Rheumazentrum Ruhrgebiet Herne, Germany and Ruhr University, Bochum, Germany.
Joint Bone Spine
November 2019
NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom. Electronic address:
N Engl J Med
May 2019
From the University Duisburg-Essen and University Hospital Essen, Essen (H.-C.D.), Boehringer Ingelheim Pharma GmbH K.G., Biberach (C.G.), Boehringer Ingelheim International GmbH, Ingelheim, Faculty of Medicine Mannheim of the University of Heidelberg, Mannheim (M.B.), Kreisklinikum Siegen, Siegen, and the University of Marburg, Marburg (M.G.), University Hospital Erlangen, Erlangen (B.K.), and Johannes Wesling Klinikum Minden and Ruhr University Bochum, Minden (P.D.S.) - all in Germany; Miller School of Medicine, University of Miami, Miami (R.L.S.); University of California at San Francisco, San Francisco (J.D.E.), and the Department of Neurology and Comprehensive Stroke Center, University of California at Los Angeles, Los Angeles (J.L.S.) - both in California; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (C.B.G.); Feinberg School of Medicine of Northwestern University, Chicago (R.A.B.); International University of Health and Welfare, Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center, Tokyo (S.U.), and the National Cerebral and Cardiovascular Center, Osaka (K.T.) - both in Japan; Boehringer Ingelheim, Singapore, Singapore (J. Kreuzer); Boehringer Ingelheim, Burlington, ON, Canada (L.C.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (D.C.); City Clinical Emergency Care Hospital, Kursk (M.C.), and the Military Medical Academy, St. Petersburg (M.O.) - both in Russia; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (G.D.); Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal (J.M.F.); F. Ass. Mutua Terrassa, Terrassa (J. Krupinski), and Servicio de Neurología, Hospital Universitario Ramón y Cajal (IRYCIS), Departamento de Medicina, Universidad de Alcalá, Madrid (J.M.) - both in Spain; Hallym University Sacred Heart Hospital, Seoul, South Korea (B.-C.L.); KU Leuven-University of Leuven, Department of Neurosciences, Experimental Neurology, VIB Center for Brain & Disease Research, University Hospitals Leuven, Department of Neurology, Leuven, Belgium (R.L.); and Hospital Policlinico Umberto I, Sapienza University, Rome (D.T.).
J Rheumatol
January 2020
From the Rheumazentrum Ruhrgebiet, Herne and Ruhr University Bochum, Herne; Rheumatologisches Praxiszentrum München; Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin; Rheumazentrum Ratingen, Ratingen; Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany.
Objective: International recommendations for the management of axial spondyloarthritis including ankylosing spondylitis (AS) recommend a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) level of disease activity of ≥ 4 to initiate treatment with biologics. We aimed to evaluate the level of disease activity used to initiate tumor necrosis factor inhibitor (TNFi) treatment and the level of responses to treatment based on different BASDAI cutoffs.
Methods: This is a posthoc analysis of the noninterventional, prospective, GO-NICE study in the subgroup of biologic-naive AS treated with golimumab (GOL) 50 mg subcutaneously once monthly.
Neurol Res Pract
February 2019
Department of Neurology, University Hospital St. Josef-Hospital Bochum, Ruhr University Bochum, Gudrunstraße 56, 44791 Bochum, Germany.
Background: Mechanical thrombectomy (MT) is a new evidence-based treatment option for large vessel occlusion in the anterior brain circulation. Using comprehensive administrative data from Germany, we analysed the nationwide development of intravenous thrombolysis (IVT) and MT in Germany between 2010 and 2016.
Methods: We considered all documented cases ( = 1,515,634) with a main diagnosis of the ICD-10-GM code I63 (ischemic stroke) and identified specific stroke recanalization therapy by using the corresponding Operating and Procedure Key for systemic thrombolysis and mechanical thrombectomy out of the DRG statistics.
Rheumatology (Oxford)
May 2019
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Objective: To evaluate the effect of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in patients with ankylosing spondylitis.
Methods: Patients opting to enrol had completed 2 years' treatment in the MEASURE 1 core study with subcutaneous secukinumab 150 or 75 mg every 4 weeks (q4Wk), following intravenous loading to Week (Wk) 4, or placebo treatment to Wk16/24. Up-titration from secukinumab 75-150 mg q4Wk was permitted following a protocol amendment.
Rheumatology (Oxford)
August 2019
Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany.
Clin Exp Rheumatol
January 2019
Rheumazentrum Ruhrgebiet, Herne, and Ruhr University, Bochum, Germany.
Large-vessel vasculitis is the most common form of primary vasculitis comprising cranial and large-vessel giant cell arteritis, Takayasu's arteritis and idiopathic aortitis. Prompt diagnosis and treatment of large-vessel vasculitis are important to prevent potentially serious emergencies such as visual loss, vascular stenosis and aneurysm formation. Temporal artery biopsy has long been the standard for diagnosing GCA - an invasive technique that lacks sensitivity compared to a clinical diagnosis that relies on a combination of clinical symptoms, elevated serum inflammatory markers and imaging findings.
View Article and Find Full Text PDFJ Cataract Refract Surg
December 2018
From the Center for Refractive Surgery (Taneri, Kießler, Rost), Eye Department, St. Francis Hospital, Muenster, and Ruhr-University (Taneri, Schultz, Elling, Dick), University Eye Clinic, Bochum, Germany.
Unilateral endophthalmitis occurred after bilateral immediately sequential intraocular collamer lens (Visian Implantable Collamer Lens) implantation for the correction of myopic astigmatism in a 49-year-old woman. The surgeries and initial recovery were unremarkable. However, after 3 days, the patient noticed increasing blurring of vision in the left eye and presented to our clinic.
View Article and Find Full Text PDFEur J Neurol
February 2019
Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Background And Purpose: In contrast to anterior circulation stroke (ACS), there is no evidence from randomized trials that mechanical thrombectomy (MT) with modern stent retrievers or thromboaspiration is safe and effective in posterior circulation stroke (PCS).
Methods: The present analysis was based on the prospective multicentre Registry on Revascularization in Ischemic Stroke Patients (REVASK) in Germany. Demographic data, periprocedural times and complications, recanalization rates, and functional outcome at discharge and after 3 months were compared between 139 consecutive patients with PCS (84.
Rheumatology (Oxford)
March 2019
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
In ankylosing spondylitis (AS), structural damage that occurs as a result of syndesmophyte formation and ankylosis of the vertebral column is irreversible. Structural damage is currently assessed by conventional radiography and scoring systems that reliably assess radiographic structural damage are needed to capture the differential effects of drugs on structural damage progression. The validity of the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) as a primary outcome measure in evaluating the effect of AS treatments on radiographic progression rates was assessed in this review.
View Article and Find Full Text PDFWorld J Orthop
December 2017
Department of Orthopedics, Trauma Surgery and Sports Medicine, Johanna Etienne Hospital, Neuss 41462, Germany.
Aim: To evaluate our modified deepening trochleoplasty combined with a balanced medial patellofemoral ligament (MPFL) reconstruction for soft tissue alignement.
Methods: Thirty-three knees with with recurrent patellar dislocations and a trochlear dysplasia in 30 patients (m/f = 12/21, mean age 24 ± 9 years) underwent a combination of a modified deepening trochleoplasty and a balanced MPFL reconstruction for a medial soft tissue alignement. After a mean follow-up period of 29 ± 23 mo, patients' return to sports, possible complications as well as the clinical outcomes using the Kujala, International Knee Documentation Committee (IKDC) and Lysholm scoring were evaluated.
J Rheumatol
February 2017
From the Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Research Center of Rheumatic Diseases, Sf. Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania; Rheumazentrum Ruhrgebiet, Herne and Ruhr-University Bochum, Herne, Germany; Patient Research Partner, People with Arthritis/Rheumatism in Europe (EULAR PARE), Zurich, Switzerland; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Objective: The effect of a disease can be categorized by a standardized reference system: the International Classification of Functioning, Disability and Health (ICF). The objective was to map the effect of psoriatic arthritis (PsA) from the patient's perspective to the ICF.
Methods: A systematic literature review was performed.
Ann Rheum Dis
April 2017
Rheumazentrum Ruhrgebiet, and Ruhr University Bochum, Herne, Germany.
Objectives: The treat-to-target (T2T) concept has been applied successfully in several inflammatory rheumatic diseases. Gout is a chronic disease with a high burden of pain and inflammation. Because the pathogenesis of gout is strongly related to serum urate levels, gout may be an ideal disease in which to apply a T2T approach.
View Article and Find Full Text PDFInt J Cardiol
July 2016
Märkische Kliniken GmbH, Klinikum Lüdenscheid, Lüdenscheid, Germany.
Background: Diabetes mellitus (DM) is an independent risk factor for cardiovascular disease and arrhythmias. Procedural data and complication rates in patients with DM undergoing catheter ablation for atrial arrhythmias are unknown.
Methods: The German Ablation Registry has been designed as a multi-center prospective registry.
J Rheumatol
May 2016
From Rheumatology, Rheumazentrum Ruhrgebiet, Herne; Ruhr-University Bochum, Bochum; Radiology, Charité Universitätsmedizin, Berlin, Germany; Biostatistics, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA.J. Braun, MD, Department of Rheumatology, Rheumazentrum Ruhrgebiet, and Ruhr-University Bochum; X. Baraliakos, MD, Department of Rheumatology, Rheumazentrum Ruhrgebiet, and Ruhr-University Bochum; K.G. Hermann, MD, PhD, Radiology, Charité Universitätsmedizin; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; B. Hsu, MD, PhD, Immunology, Janssen Research & Development LLC.
Objective: To assess vascular endothelial growth factor (VEGF) correlations with new bone formation and bone marrow edema in patients with ankylosing spondylitis (AS) treated with golimumab (GOL).
Methods: Following placebo control (through weeks 16 and 24), GO-RAISE (A Multicenter Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondylitis; ClinicalTrials.gov: NCT00265083) all patients received GOL; sera/images were available at weeks 0, 104, and 208.
Clin Exp Rheumatol
December 2015
Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Germany.
Although different classification criteria have been developed for psoriatic arthritis (PsA) and spondyloarthritis (SpA), a clear distinction is still not always possible in daily practice. In addition, clinical examination of patients initially diagnosed as PsA due to peripheral symptoms and skin lesions may also show inflammation in the axial skeleton causing inflammatory back pain, stiffness and changes on imaging including sacroiliitis, spondylitis and syndesmophyte formation, similar to what is known from ankylosing spondylitis (AS), the prototype of SpA. However, and in contrast to patients with AS, the long-term radiographic progression of patients with axial disease in PsA seems to be rather independent from spinal mobility.
View Article and Find Full Text PDF